Market Context — Why This Technology, Why Now

Aging global populations and lifestyle changes are driving a surge in chronic diseases, making early and non-invasive diagnostics a top priority for healthcare systems worldwide. There is increasing pressure to reduce healthcare costs while improving patient outcomes, pushing demand for technologies that enable preventative care and personalized treatment pathways. This technology aligns perfectly with these trends, offering a solution that enhances diagnostic accuracy and patient comfort.

Key Competitive Advantages
01

Provides detailed, non-invasive fibrosis imaging with zero patient burden, enabling early and continuous monitoring for optimized treatment strategies.

02

Utilizes combined acoustic and electromagnetic waves to acquire multi-faceted information, significantly enhancing diagnostic accuracy for complex fibrosis pathologies.

03

Compares the area of visualized fibrotic regions against a threshold, establishing objective, reproducible diagnostic criteria independent of physician experience.

Market Opportunity
Liver Disease Diagnostics
$350M globally (AI est.)
Rising incidence of non-alcoholic steatohepatitis (NASH) and cirrhosis drives urgent demand for non-invasive, high-precision liver fibrosis diagnosis. This technology could contribute to early detection and disease monitoring.
Major diagnostic imaging companies Pharmaceutical companies developing liver disease therapies Specialized medical device manufacturers for gastroenterology
Cardiovascular Disease Diagnostics
$250M globally (AI est.)
Myocardial fibrosis is a leading cause of heart failure; early diagnosis and intervention significantly impact patient prognosis. This technology could open new avenues for non-invasive cardiac assessment.
Cardiovascular medical device OEMs Diagnostic imaging solution providers Biotech firms focused on heart health
Kidney Disease Diagnostics
$200M globally (AI est.)
The progression of chronic kidney disease (CKD) is closely linked to fibrosis. Early diagnosis and intervention before dialysis initiation could significantly impact healthcare economics.
Nephrology device manufacturers Clinical diagnostic laboratories Healthcare IT companies with diagnostic platforms
Drug Development & Clinical Trials
$200M globally (AI est.)
For new drug development targeting fibrosis-related diseases, a non-invasive, quantitative evaluation tool could significantly improve clinical trial efficiency, shortening development times and increasing success rates.
Contract Research Organizations (CROs) Major pharmaceutical companies Biotech startups in fibrosis research
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

The patent's journey through multiple rejections and a pre-appeal examination procedure underscores its robust patentability and strong defensive capabilities against future invalidation claims. With 13 comprehensive claims, this patent provides broad technical protection for non-invasive fibrosis measurement using acoustic and electromagnetic wave integration, establishing a solid foundation for commercialization.

Competitive White Space

This patent focuses on biological tissue fibrosis. White space exists in applying similar multi-modal sensing to non-biological material diagnostics or integrating advanced AI for predictive analytics beyond current image quantification.

Economic Impact
~$55M/year estimated diagnostic cost reduction per 100,000 patients (est.), with potential for up to 15% overall annual healthcare cost reduction (est.).
estimated ROI · USD · AI analysis
ROI Calculation Logic

For liver fibrosis diagnosis, replacing a traditional invasive biopsy (~$650/procedure (AI est.)) with this non-invasive technology (~$100/procedure (AI est.)) could save ~$550/patient (AI est.). Applying this to 100,000 patients annually could contribute to ~$55M (AI est.) in healthcare cost reductions. Furthermore, early detection and treatment could prevent severe progression, potentially reducing related annual healthcare expenditures by up to 15%.

Speed to Market
5× faster than in-house development
This technology, an invention by a national R&D agency, is presumed to have completed fundamental technical principle demonstrations. Its components, such as the acoustic wave irradiator and electromagnetic wave receiver, can leverage existing medical device technologies, minimizing the need for new elemental technology development. This could shorten development time by approximately 4 years compared to in-house development, enabling faster market entry and revenue generation for licensees.
Competitive Positioning

X: Diagnostic Accuracy & Non-Invasiveness
Y: Early Detection & Treatment Efficacy

Business Models & Applications
🏥 Diagnostic Device Sales
This model involves selling the fibrosis measurement device to medical institutions and testing centers. By emphasizing high precision and non-invasiveness, it aims to promote replacement of existing diagnostic equipment or new introductions, supporting digital transformation in healthcare.
🧪 Testing Service Provision
This model offers fibrosis measurement services using this technology, processing samples or patient data from medical institutions. It lowers adoption barriers for healthcare providers by eliminating the need for specialized knowledge or capital investment, encouraging widespread use.
💊 Pharmaceutical Development Support
This model provides the technology to pharmaceutical companies as a tool for efficacy measurement and monitoring during clinical trial phases for new drugs targeting fibrosis-related diseases. It could contribute to shortening development periods and increasing success rates, accelerating new drug market entry.
Adjacent Application Opportunities
🥩 Food Quality Assessment
Meat Freshness & Quality Indicator
This technology could non-invasively measure the degree of fibrosis in meat, providing objective indicators for texture and quality. It could be applied to quality control for aged meats or in processed food development, potentially reducing food waste and increasing product value.
👕 Textile & Material Degradation Diagnostics
Non-Destructive Industrial Material Inspection
The technology could non-destructively detect internal degradation (fibrosis) in composite materials or industrial fibers used in bridges and aircraft. This could optimize maintenance schedules and prevent accidents, contributing to improved infrastructure safety.
🌳 Tree & Timber Diagnostics
Tree Health Assessment System
This technology could non-invasively measure fibrosis (decay or degradation) within tree tissues, assessing the risk of falling trees. Applied to urban green space management, cultural property preservation, or timber quality assessment, it could offer new value for maintaining societal infrastructure.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technical Feasibility & Requirements Definition
Duration: 4 months
Detailed analysis of the licensee's business domain and needs to define the technology's application scope and specific product requirements. Evaluation of integration possibilities with existing systems to formulate an optimal deployment plan.
Phase 2: Prototype Development & Validation
Duration: 9 months
Development of a prototype based on defined requirements and initial performance evaluation. Subsequent validation through clinical data and real-world trials to verify technology effectiveness and safety, gathering data for regulatory submission.
Phase 3: Product Commercialization & Market Launch
Duration: 9 months
After regulatory approval, establish mass production systems and finalize product adjustments. Simultaneously, develop market entry strategies, establish sales channels, and initiate marketing activities to achieve rapid market penetration.
Technical Feasibility
This technology, which measures biological tissue properties using a combination of an acoustic wave irradiator and an electromagnetic wave receiver, could be developed based on existing ultrasound diagnostic equipment and electromagnetic sensor technologies. Signal extraction, imaging, and area comparison are primarily software-based, making integration into existing medical imaging processing systems technically feasible. Significant new capital investment is likely not required.
Success Scenario
Upon adoption, this technology could enable routine, non-invasive fibrosis diagnosis in clinical settings, replacing traditional invasive biopsies and reducing patient burden. This could lead to early detection and precise monitoring of chronic disease progression, optimizing treatment efficacy and preventing severe complications, potentially reducing annual healthcare costs by up to 15%.
Patent Record
APPLICATION NO.
特願2021-542585
REGISTRATION NO.
7572063
FILING DATE
2020/07/01
GRANT DATE
2024/10/15
EXPIRATION DATE
2040/07/01
PATENT HOLDER
国立研究開発法人科学技術振興機構
Examination History
2023年04月17日
出願審査請求書
2024年05月21日
拒絶理由通知書
2024年05月24日
意見書
2024年05月24日
手続補正書（自発・内容）
2024年08月20日
拒絶査定
2024年09月03日
手続補正書（自発・内容）
2024年09月10日
審査前置移管
2024年09月17日
審査前置移管通知
2024年09月24日
特許査定
2024年09月27日
審査前置登録